Leap Therapeutics Inc LPTX:NASDAQ

Last Price$1.31NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/13/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$1.06 (1)
Ask (Size)$1.34 (1)
Day Low / HighN/A - N/A

Leap Therapeutics to Report 'Encouraging Results' From Phase 2a Trial of Combination Treatment for Gastric Cancer -- Shares Jump in Pre-Market

6:06AM ET 1/19/2022 MT Newswires
Leap Therapeutics (LPTX) said late on Tuesday the combination of anti-Dickkopf-1, or DKN-01, with tislelizumab "continues to demonstrate encouraging results" in patients with gastric and gastroesophageal junction cancer.

The company said updated data from a Phase 2a clinical trial evaluating DKN-01 in combination with tislelizumab, BeiGene's anti-PD-1 antibody, will be presented at a symposium on Jan. 20-22.

New data demonstrate "compelling efficacy" from this combination regimen, driven by enhanced clinical responses and survival benefits.

Also to be presented are initial findings from the still-enrolling Part B of the trial, studying the same combination in second-line advanced gastric and gastroesophageal junction patients with high tumoral DKK1 expression, showing the treatment is "well tolerated with encouraging objective responses observed."

Shares of the company jumped 8.5% in the most recent pre-market activity on Wednesday.

Price: 2.96, Change: +0.24, Percent Change: +8.82